Bookmark and Share

2015 Cancer Biology T-32 Training Grant

For more information Contact:  

 Marcina Garner, Program Manager

 University of Maryland School of Medicine
800 W. Baltimore Street, Room 216
Baltimore, MD 21201
Phone 410-706-8114; Fax 410-706-8121

  Talia Bailey, Program Administrator
Center for Vascular & Inflammatory Diseases
800 W. Baltimore Street, Room 212
Baltimore, MD  21201
410-706-8121 (fax)  

Toni M. Antalis, Ph.D., Co-Director
Professor of Physiology,
University of Maryland School of Medicine
410 706 8222

Curt I. Civin, M.D., Co-Director
Associate Dean for Research,
University of Maryland School of Medicine

Download 2015 Guidelines and Application



The Cancer Biology T32 Training Program at the University of Maryland is a prestigious program designed to train predoctoral students and postdoctoral fellows in fundamental mechanisms of cancer biology at the molecular, cellular and organism levels.  The program takes advantage of the multidisciplinary and highly interactive research environment within the University of Maryland Greenebaum Cancer Center and at the University of Maryland Baltimore campus to provide outstanding training in critical areas of basic and translational cancer research. A guiding philosophy is that Cancer Biology T32 training program must provide integrative activities that illuminate the inter-relatedness of basic cancer research and clinical medicine.  Support for the program has been provided from a training grant from the NIH National Cancer Institute.

Major advances in our understanding the complexity of cancer and tumor cell biology requires a quantitative understanding of the many interconnected networks of molecules that comprise our cells and tissues, their interactions, and their regulation.  A collective strength of the investigators of this training program is the integration of multiple, diverse disciplines that encompass experimental approaches and didactic knowledge from biochemistry, cell biology, epidemiology, genetics, immunology, microbiology, pharmacology, molecular biology, pathology, and physiology, in addition to the clinical oncologic sciences that are involved in human cancer prevention, detection, diagnosis, and treatment. The goal of Cancer Biology training program is to provide an integrative research experience with appropriate mentoring and career guidance to facilitate the inter-relatedness of basic cancer research and clinical medicine. The T32 Cancer Biology program is designed to meet this objective through appropriate didactic and research components, interactive seminars and workshops, and professional development that should provide a solid foundation for a long term and successful career in cancer research.

The T32 Cancer Biology Training Program has positions for predoctoral students, postdoctoral fellows and for residents and clinical fellows interested in cancer research.

To be considered for a position on this training grant, a faculty mentor will be identified and a research plan will be developed in conjunction with the mentor.

The award of a trainee slot on this grant is for a 1 year period, and is renewable by competitive application for a 2nd and possibly a 3rd year, however each year involves a competitive renewal with no greater assurance of funding for ongoing applicants than for new applicants. Trainees and mentors are strongly encouraged to apply for individual competitive fellowships or for other cancer research grant support during their 1st or 2nd year in the program. All predoctoral and postdoctoral fellows supported by the Cancer Biology T32 training program will be encouraged to participate in didactic components, interactive seminars and workshops, and professional development to appropriate to their background, in order to provide a solid foundation for a long term and successful career in cancer research. 

Funding support from this grant is limited to the levels mandated by NIH guidelines. Salary may be supplemented from other single or combined sources, such as research grants, professional fees, etc. Health insurance and support for travel is provided. For M.D. trainees, support from the T32 Training Program provides ‘protected time’ for immersion in the laboratory and it is required that patient care responsibilities will be limited to <10% effort (one half day per week), primarily to help complete long-term patient care experience necessary for their subspecialities and to maintain patient-care skills. 

Qualifications for Trainee Slots:

  • All appointments to this training grant are restricted to U.S. citizens and permanent residents.
  • Applicants must be committed to cancer research.
  • Predoctoral applicants must be enrolled in GPILS (PhD or MD/PhD program) at the University of Maryland Baltimore.  Students must have completed the required courses: GPLS 790 - Advanced Cancer Biology and GPLS 665 - Cancer Biology: From Basic Research to the Clinic.
  • Postdoctoral applicants must have completed doctoral level training (e.g. PhD, MD, MD/PhD, PharmD, DDS or equivalent).  Evidence of scholarly productivity in the form of publications or planned publications is highly desirable.  Post-doctoral trainees from Residency and Fellowship training programs (e.g. Radiation Oncology, Hematology/Oncology, and Oncology residents from OB-GYN, Otorhinolaryngology, Pathology, Pediatrics, Medicine or Surgery residency programs) are encouraged to apply. 


Download 2015 Guidelines and Application




Faculty Mentors

Research Focus  

Antalis, Toni, icon 

Regulation of signaling pathways affecting cancer growth and metastasis, vascular biology, angiogenesis, and inflammation by serine proteases and their inhibitors.

Antony, Paul Andrew, icon 

To develop therapies that use the immune system to fight cancer, with an emphasis on 1) adoptive immunotherapy of cancer using tumor-specific CD4 T cells or tumor-specific CD8+ T cells and 2) the use of cytokine therapies especially IL-15 and cytokine antibody immune complexes.

Aurelian, Laure, icon 

Molecular virology of herpes simplex type 2 (HSV2) and signaling pathways involved in cell proliferation and apoptosis with a focus on targeting of H11, a product that has structural similarities to an HSV2 for the treatment of cutaneous melanoma

Baer, Maria, icon 

Signaling pathways affecting drug resistance mechanisms in acute myeloid leukemia

Basile, John, DDS, icon 

Tumor-induced angiogenesis

Bentzen, Soren icon   Biostatistical methodology for the design and analysis of cancer combination studies; adaptive clinical trial designs, risk and prognostic modeling, regularized regression models for genomic and proteomic data, statistical analysis for the evaluation of accuracy of diagnostic tests and cancer biomarkers and epidemiology including hierarchical modeling in cancer control studies.

Brodie, Angela icon 

Internationally recognized for her pioneering work on the development of aromatase inhibitors as a treatment for breast cancers.

  Bromberg, Jonathan S M.D.  The immunology of chemokines and cell migration on the immune response; regulation of the T cell response in immunosuppression and cancer therapy 

Carey, Gregory, icon 

Regulation of signal protein activity and fate by reactive oxygen species (ROS); mechanisms of action of natural, synthetic and biological anti-tumor agents.

Carrier, France, icon 

DNA damage response, activation of RNA binding proteins, Histone deacetylase Inhibitors, Translational research, tumor suppressor genes (p53).

Civin, Curt, icon 

Cell and molecular biology of normal hematopoiesis and leukemia

Cullen, Kevin J., icon 

Molecular markers of treatment response and outcome in head and neck cancer

Davidoff, Amy, icon 

Comparative effectiveness research in cancer, an important component of the translational research spectrum, assessing cancer diagnostic and treatment approaches once they are broadly disseminated.

Devine, Scott, icon 

Human genetic variation caused by transposable genetic elements and small insertions/deletions (INDELs)

Donnenberg, Michael, M.D. email icon 

Molecular Pathogenesis of E. coli infections; Role of E. coli in colorectal carcinogenesis.

Dorsey, Susan G., icon 

The molecular, cellular and genetic correlates of the development and persistence of cancer-treatment related chronic pain.

Eckert, Richard, icon 

MAPK signaling and transcriptional control of gene expression

Edelman, Martin, M.D. email icon 

Clinical trials and translational therapeutics in thoracic oncology

Feng, Pei, M.D., icon 

Apoptotic effect of zinc in targeting prostate cancer; the mechanism of cell apoptosis and autophagy in the prostate and pancreatic cancer models; HDACI effect on cancer cell growth in in vivo and in vitro.  

Franklin, Renty, icon 

The role of testosterone and prolactin in the progression of prostate cancer and zinc signaling in proliferation and apoptosis of prostate cancer cells.

Fraser-Liggett, Claire, icon 

The role of human gut microbial communities in health and various diseases including obesity, inflammatory bowel disease, and colon cancer.

Fulton, Amy, icon 

Biologic determinants of cancer metastasis; biologic basis of cancer disparities; role of cyclooxygenase pathway in tumor biology; role of chemokine receptors in tumor biology

  Gallo, Robert  C. M.D.  HIV biology and vaccine development

Gartenhaus, Ron, icon 

The biology of the MEK/ERK pathway vis-à-vis its role in regulating the MCT-1 oncogene and how they contribute to lymphomagenesis.

Garzino-Demo, Alfredo  Ph.D.  Molecular virology; role of the immune system and host factors in controlling HIV infection. HIV proteins in murine models of lymphomagenesis

Goldblum, Simeon, icon 

Regulation of the endothelial paracellular pathway and tyrosine phosphorylation signaling events that influence endothelial participation in proangiogenic and septic/inflammatory processes.

Hamburger, Anne, icon 

Growth factor receptor control of breast and prostate cancer. Novel therapy for HER2 positive hormone refractory breast cancer

Hassel, Bret A., icon 

Molecular mechanisms of antiproliferative activities by the tumor suppressor RNase-L. Posttranscriptional regulation of mRNA turnover, and alteration of this control in tumor cells.

Jiang, Feng, icon 

Identifying cancer-related genes that are involved with the transformation and early progression of tumors and translating these findings into clinical applications for enhancing cancer diagnosis.

Kaetzel,  David Ph.D.
Molecular mechanisms underlying metastasis driving mutations in melanoma

Kalvakolanu, Dhan V., icon 

Novel tumor suppressor genes, apoptosis; autophagy, signal transduction by Interferons and other cytokines; transcriptional regulation of gene expression

Keegan, Achsah D., icon 

Cytokine signaling, apoptosis, chemosensitivity, macrophage activation, allergic lung inflammation

Kim, Anthony., Ph.D.    Translational neuro-oncology; integrating innovative biophysical techniques and advanced therapeutic delivery platforms with brain cancer biology to solve clinical problems and improve patient outcomes.

Lindberg, Iris, icon 

Structure and function of proprotein convertases; convertase inhibition in cancer

  Losert, Wolfgang Ph.D. Department of Physics, University of Maryland College Park;  application of cutting-edge mathematical-physical principles of analysis to large-scale data for cancer research, diagnostics and therapeutics.

Lu-Chang, A-Lien, Ph.D. email icon 

The mechanism and regulation of DNA repair by cell cycle checkpoints and histone/protein deacetylases

Mao, Li, icon 

Molecular and genetic alterations and their roles in the multistep process of upper aerodigestive tract malignancies.

Martin, Stuart S., Ph.D. email icon 

Cytoskeletal and apoptotic determinants of circulating breast tumor cell survival and metastasis.

Mixson, A. James, icon 

Novel gene therapy approaches toward cancer. Non-viral delivery of antiangiogenic genes utilizing either in vitro or in vivo model systems.

Montaner, Silvia, Ph.D., icon 

Molecular pathogenesis of Kaposi’s sarcoma, endothelial cell biology, inflammation-mediated angiogenesis.

Passaniti, Antonino, icon 

Transcriptional regulation of tumor angiogenesis and breast cancer metastasis; metabolic function of vascular endothelial cells in obesity

Pauza, C. David, icon 

Tumor immunity and immunotherapy, tumor recognition and killing by gd T cells, AIDS-related malignancies, oncogenic mechanisms for HIV, Hepatitis C Virus and Human Papillomavirus in immunodeficient patients.

Qiu, Yun, icon 

Molecular mechanisms underlying drug resistance in prostate cancer, specifically autocrine/paracrine factors that activate protein kinase cascades controlling antiapoptotic signaling to confer resistance to therapies.

Rassool, Feyruz V., icon 

Production of reactive oxygen species (ROS), DNA damage and repair responses in leukemia leading to genomic instability and disease progression.

Raufman, Jean-Pierre, M.D. email icon 

Muscarinic receptors and ligands in colon cancer

Ross, Douglas, M.D., icon 

Cancer drug resistance; Molecular pharmacology; Cancer stem cells

ABC transporters and drug resistance and disposition; Clinical trials with novel agents; Transcriptional regulation of breast cancer resistance protein/ABCG2; Palliative care education for medical students and residents

Sarkar, Rajabrata, M.D. icon 

Regulation of angiogenesis in vivo. Activation of p53 and mechanisms of p53 modulation of angiogenesis and arteriogenesis.

Sausville, Edward, M.D., icon 

Molecular mechanisms of novel anti-neoplastic agent action, clinical studies of novel cancer therapies

Shapiro, Paul, icon 

Kinase signaling cascades and regulation of cell proliferation, development of small molecular weight compounds that selectively inhibit MAP kinase interactions with substrate proteins.

Stone, Maurine, Ph.D.

Behavior and control of the tongue, application of MRI and clinical ultrasound for use with the tongue, compensatory tongue motion and speech quality after tongue cancer surgery

Strickland, Dudley, icon 

Mechanisms by which the tumor suppressor gene LRP1b regulates tumor cell growth; mechanisms by which LDLR family members regulate the PDGF-receptor; inflammation and vascular disease.

Strome, Scott, icon 

The immunotherapy of head and neck cancer, with a focus on mechanisms to prime and/or boost the antitumor immune response.

Tamada, Koji, M.D., icon 

Regulation of anti-tumor immune responses, development of novel cancer immunotherapy, cloning and characterization of immune-regulatory co-signaling molecules.

Wang, Jian-Ying M.D. Ph.D   The roles and mechanisms of cellular polyamines and polyamine-regulated genes in the control of intestinal epithelial cell proliferation, apoptosis, migration, and cell-to-cell interactions.

Webb, Tonya, icon 

Cancer immunology, specifically investigating mechanisms by which tumors evade immune detection as well developing novel immunotherapeutic strategies for the treatment of melanoma, breast and prostate cancers.

Weber, David J. , icon 

Structure/function relationships of calcium-binding proteins and their biological targets, cancer biology, structural biology, drug design

Williams, Mark, icon 

Regulation of hematopoietic cell development and function by NADPH oxidases and reactive oxygen species (ROS); Effect(s) of ROS and oxidative stress on immune responses in vitro and in vivo, inflammation and stem cell function.

Wilson, Gerald, icon 

Mechanisms regulating messenger RNA decay, post-transcriptional regulation of oncoprotein and cytokine expression.

Winkles, Jeffrey A., icon 

Role of the TWEAK/Fn14 axis in tumor growth and metastasis.

Woodworth, Graeme F., M.D., icon   Translational neuro-oncology with a research focus on delivering effective therapeutics to brain-invading, unresectable glioblastoma cancer cells.

Yang, Austin, icon 

Mass Spectrometry; Roles of phosphorylation on the assembly of receptor and signaling complexes In cancer and aging.

Zhan, Steven, icon 

Cell motility, tumor invasion, metastasis, cell biology, genome instability, angiogenesis, and tyrosine kinase signaling pathways.

Zhang, Li, icon 

Myeloid-derived suppressor cells in tumor growth and metastasis.

Zhou, Qun M.D. Ph.D.   The roles of microRNAs (miRNAs) in breast cancer stem cells and malignant transformation